Micronutrient composition to prevent and reverse protein glycation during oxidative stress in human

Abstract

The Mix as micronutrient composition is a combination of Alpha-Ketoglutaric Acid, Niacinamide or Niacin, L Proline, L Glutamine, L Citrulline, Sodium Pyruvate, Pantothenic Acid, L Cysteine or N-acetyl Cysteine, Magnesium Malate, Magnesium Citrate, and Methionine. Mix is effectively used to treat diseases that is due to oxidative stress. More specifically the Mix and Core as micronutrient composition is effective in reversing glycation in diabetes.

What is claimed is: 
     
         1 . A micronutrient composition, comprising of:
 micronutrient composition comprises of Alpha-Ketoglutaric Acid, Niacinamide or Niacin, L Proline, L Glutamine, L Citrulline, Sodium Pyruvate, Pantothenic Acid, L Cysteine or N-acetyl Cysteine, Magnesium Malate, Magnesium Citrate, Methionine, and optionally adding one or combination of pharmaceutically acceptable carriers or excipient or liquefied propellant or buffer or pH regulator or stabilizer or coating or flavoring agent optionally formulated as a tablet, coated tablet, capsule, pill, intranasal, lozenges, emulsion, pastilles, suppository, paste or injectable solution.   
     
     
         2 . The micronutrient composition of  claim 1 , comprising of the Alpha-Ketoglutaric Acid 10 mg-30000 mg, Niacinamide or Niacin 1 mg-10000 mg, L Proline 10 mg-30000 mg, L Glutamine 10 mg-50000 mg, L Citrulline 10 mg-20000 mg, Sodium Pyruvate 10 mg-50000 mg, Pantothenic Acid 0.1 mg-200 mg, L Cysteine or N-acetyl Cysteine 10 mg-20000 mg, Magnesium Malate 10 mg-20000 mg, Magnesium Citrate 10 mg-30000 mg, Methionine 10 mg-20000 mg. 
     
     
         3 . The micronutrient composition of  claim 2 , consisting of the Alpha-Ketoglutaric Acid, Niacinamide or Niacin, L Proline, L Glutamine, L Citrulline, Sodium Pyruvate, Pantothenic Acid, L Cysteine or N-acetyl Cysteine, Magnesium Malate, Magnesium Citrate, and Methionine. 
     
     
         4 . The micronutrient composition of  claim 3 , consisting of the Alpha-Ketoglutaric Acid 10 mg-30000 mg, Niacinamide or Niacin 1 mg-10000 mg, L Proline 10 mg-30000 mg, L Glutamine 10 mg-50000 mg, L Citrulline 10 mg-20000 mg, Sodium Pyruvate 10 mg-50000 mg, Pantothenic Acid 0.1 mg-200 mg, L Cysteine or N-acetyl Cysteine 10 mg-20000 mg, Magnesium Malate 10 mg-20000 mg, Magnesium Citrate 10 mg-30000 mg, and Methionine 10 mg-20000 mg. 
     
     
         5 . The micronutrient composition of  claim 1 , wherein the micronutrient composition is formulated for treating a human to reverse an oxidative stress in a specific disease. 
     
     
         6 . The micronutrient mixture of  claim 5 , wherein the specific disease is diabetes. 
     
     
         7 . The micronutrient composition of  claim 1 , wherein the micronutrient composition is formulated for improving, protecting and mitigating from a specific disease that is initiated by an antioxidant cellular reaction. 
     
     
         8 . The micronutrient composition of  claim 7 , wherein the specific disease is a diabetes, cardiovascular disease, Alzheimer's and inflammation which accelerates aging of tissues. 
     
     
         9 . A method of treating an antioxidant prone disease, comprising;
 administering to a human in need thereof a micronutrient composition, wherein the micronutrient composition comprises of Alpha-Ketoglutaric Acid 10 mg-30000 mg, Niacinamide or Niacin 1 mg-10000 mg, L Proline 10 mg-30000 mg, L Glutamine 10 mg-50000 mg, L Citrulline 10 mg-20000 mg, Sodium Pyruvate 10 mg-50000 mg, Pantothenic Acid 0.1 mg-200 mg, L Cysteine or N-acetyl Cysteine 10 mg-20000 mg, Magnesium Malate 10 mg-20000 mg, Magnesium Citrate 10 mg-30000 mg, and Methionine 10 mg-20000 mg and optionally one or a combination of pharmaceutically acceptable carriers or excipient or liquefied propellant, buffer, pH regulator, stabilizer, coating or flavoring agent, wherein the micronutrient composition is formulated as a tablet, coated tablet, capsule, pill, intranasal, lozenges, emulsion, pastilles, suppository, paste or injectable solution.   
     
     
         10 . The method of  claim 9 , further comprising;
 decreasing formation of an advanced glycation end product that were formed due to an oxidative stress.   
     
     
         11 . The method of  claim 9 , further comprising;
 Reversing formation of an advanced glycation end product, wherein the advanced glycation end product is caused by excess glucose in the human that were formed due to oxidative stress.   
     
     
         12 . The method of  claim 9 , further comprising;
 promoting mitobiogenesis in the muscle cells and protecting microglial cells from death caused by oxidative stress.   
     
     
         13 . The method of  claim 9 , further comprising;
 lowering a level protein glycation in human.   
     
     
         14 . A method of using a micronutrient composition, comprising;
 administering to a human in need thereof the micronutrient composition, wherein the micronutrient compound is a mix of Alpha-Ketoglutaric Acid 10 mg-30000 mg, Niacinamide or Niacin 1 mg-10000 mg, L Proline 10 mg-30000 mg, L Glutamine 10 mg-50000 mg, L Citrulline 10 mg-20000 mg, Sodium Pyruvate 10 mg-50000 mg, Pantothenic Acid 0.1 mg-200 mg, L Cysteine or N-acetyl Cysteine 10 mg-20000 mg, Magnesium Malate 10 mg-20000 mg, Magnesium Citrate 10 mg-30000 mg, and Methionine 10 mg-20000 mg, wherein the micronutrient composition is formulated as a tablet, coated tablet, capsule, pill, intranasal, lozenges, emulsion, pastilles, suppository, paste or injectable solution and optionally adding one or a combination of pharmaceutically acceptable carriers or excipient or liquefied propellant, buffer, Ph regulator, stabilizer, coating or flavoring agent; and   treating a human suffering from an oxidative stress induced disease by reducing a glycation optionally protein and glucose.   
     
     
         15 . The m method of using a micronutrient composition  claim 14 , comprising;
 decreasing formation of an advanced glycation end product that were formed due to oxidative stress.   
     
     
         16 . The method of using a micronutrient composition of  claim 14 , comprising;
 Reversing formation of an advanced glycation end product, wherein the advanced glycation end product is caused by excess glucose in the human and formed due to oxidative stress.   
     
     
         17 . The method of using a micronutrient composition of  claim 14 , comprising;
 promoting mitobiogenesis in the muscle cells and protecting microglial cells from death caused by oxidative stress.   
     
     
         18 . The method of using a micronutrient composition of  claim 14 , comprising;
 lowering a level protein glycation in human that were formed due to oxidative stress.